What are the recommended treatments for migraines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Migraine Treatment

The recommended first-line treatment for acute migraine attacks is nonsteroidal anti-inflammatory drugs (NSAIDs), followed by triptans as second-line therapy when NSAIDs fail or for moderate to severe attacks. 1

Acute Treatment Algorithm

First-Line Therapy

  • NSAIDs (most consistent evidence for effectiveness, well-tolerated, cost-effective)
    • Ibuprofen 400-600mg
    • Naproxen sodium 500-550mg
    • Aspirin
    • Acetaminophen-aspirin-caffeine combination
    • Note: Acetaminophen alone is ineffective for migraine treatment 1

Second-Line Therapy

  • Triptans (when NSAIDs fail or for moderate to severe attacks)
    • Sumatriptan 50mg orally (optimal balance of efficacy and tolerability) 1, 2
    • Sumatriptan 100mg orally (may provide greater effect but with more adverse events) 2, 3
    • Sumatriptan 6mg subcutaneously (for severe attacks or significant nausea/vomiting) 1, 4
    • Rizatriptan 10mg orally
    • Naratriptan or Zolmitriptan (oral formulations)

Important Triptan Contraindications

  • Uncontrolled hypertension
  • Basilar or hemiplegic migraine
  • Cardiovascular disease or risk factors
  • Concurrent use with MAO-A inhibitors 1

Route of Administration Considerations

  • Consider non-oral routes (subcutaneous, nasal) for patients with significant nausea/vomiting 1
  • Subcutaneous administration provides more rapid pain relief than other routes 4
  • Taking medication early when pain is mild is more effective than waiting until pain is moderate or severe 4

Adjunctive Therapy

  • Antiemetics when nausea is a significant component 1
  • Rescue medications for severe attacks unresponsive to first/second-line treatments:
    • Opioids (e.g., meperidine)
    • Butalbital-containing compounds 1

Preventive Treatment

When to Consider Prevention

  • ≥2 migraine attacks per month with significant disability
  • Acute treatments used more than twice weekly 1

Preventive Options

  1. Beta blockers

    • Propranolol 80-240 mg/day (high strength of evidence) 1
  2. Tricyclic antidepressants

    • Amitriptyline 30-150 mg/day (particularly effective for mixed migraine and tension-type headaches) 1
    • Monitor for side effects: drowsiness, weight gain, anticholinergic symptoms
  3. Anticonvulsants 1

  4. CGRP monoclonal antibodies (moderate to high strength of evidence) 1

Medication Limitations to Prevent Medication Overuse Headache

  • Triptans: No more than 9 days per month 1
  • OTC medications: No more than 14 days per month
  • NSAIDs: No more than 15 days per month

Dosing Guidelines for Sumatriptan

  • If migraine hasn't resolved 2 hours after taking sumatriptan, a second dose may be administered
  • Maximum daily dose: 200mg in a 24-hour period 2
  • For patients with mild to moderate hepatic impairment, maximum single dose should not exceed 50mg 2

Patient Education and Monitoring

  • Track headache frequency, severity, duration, disability, response to treatment, and adverse effects using a headache diary
  • Identify and avoid migraine triggers (alcohol, caffeine, certain foods, stress, fatigue, perfumes, fumes, glare, flickering lights) 1
  • Regular aerobic exercise, maintaining regular sleep schedule, adequate hydration, and relaxation techniques are recommended non-pharmacological approaches 1

Common Pitfalls and Caveats

  1. Medication overuse headache - Strictly adhere to recommended medication limitations
  2. Triptan recurrence - Migraine may recur within 24-48 hours in approximately 40% of patients treated with sumatriptan due to its short half-life (about 2 hours) 5
  3. Cardiac risk - Cardiac monitoring is recommended for first-time use of subcutaneous sumatriptan in patients with cardiovascular risk factors 1
  4. Treatment assessment - Evaluate efficacy of preventive treatments after 2-3 months for oral preventives and 3-6 months for CGRP monoclonal antibodies 1
  5. Progression risk - Chronic migraine is associated with greater burden, more frequent comorbidities, and possibly progressive brain abnormalities, making appropriate treatment essential to prevent progression from episodic to chronic migraine 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.